Gilead Sciences upgraded by Morgan Stanley with a new price target

1/10/25 7:52:44 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley upgraded Gilead Sciences from Equal-Weight to Overweight and set a new price target of $113.00 from $87.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GILD

Date	Price Target	Rating	Analyst
4/22/2025	$125.00	Overweight	Cantor Fitzgerald
3/4/2025	$115.00 → $132.00	Outperform	Oppenheimer
2/18/2025	$120.00	Hold → Buy	Deutsche Bank
2/13/2025	$108.00	Hold → Buy	DZ Bank
1/10/2025	$87.00 → $113.00	Equal-Weight → Overweight	Morgan Stanley
12/10/2024	$109.00	Buy	BofA Securities
11/15/2024	$110.00	Outperform	Wolfe Research
11/14/2024	$125.00	Buy	Citigroup